

Vision

To improve patient outcomes by improving the safety, cost-effectiveness and scalability of current and future gene therapies.

Mission

To develop next-generation platform technologies using lipid nanoparticles (LNPs) for the safe and efficient delivery of nucleic acids to a variety of tissues.

Portfolio

- Novel, proprietary, economical **lipids for nucleic acid delivery** with proven efficacy *in vivo* and *in vitro*
- **Lipid nanoparticle (LNP) formulations** to encapsulate a variety of payloads (siRNA, mRNA, pDNA, etc.)
- Novel proprietary **RNA caps** that greatly increase the efficiency of mRNA translation
- Different **mRNA constructs**


NanoVation Therapeutics™ (NTx) provides a one-stop IP portfolio to empower the development of genetic medicines.

We partner to deliver genetic medicines, beginning with mRNA synthesis and LNP formulation, through to ensuring efficacy, potency and safety, and culminating with the option for our partners to license customized platform technologies.

Toolbox

Our toolbox has two components:

- **Cargo**, comprised of mRNA modifications, and
- **Delivery Systems**, comprised of unique ionizable lipid libraries, LNP compositions, and surface modifications



WE INNOVATE WE DELIVER

NTx is delivering tomorrow's genetic medicines, TODAY.

NanoVation Therapeutics™

4th Floor, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada
nanovationtx.com

Leadership



Pieter Cullis
Co-Founder, Board Chair



Marco Ciufolini
Co-Founder, VP Chemistry



Dominik Witzigmann
Co-Founder, CEO



Jayesh Kulkarni
Co-Founder, CSO



Eric Jan
Co-Founder



Christian Kastrop
Co-Founder